KR830010065A - 치료제의 제조방법 - Google Patents

치료제의 제조방법 Download PDF

Info

Publication number
KR830010065A
KR830010065A KR1019820001506A KR820001506A KR830010065A KR 830010065 A KR830010065 A KR 830010065A KR 1019820001506 A KR1019820001506 A KR 1019820001506A KR 820001506 A KR820001506 A KR 820001506A KR 830010065 A KR830010065 A KR 830010065A
Authority
KR
South Korea
Prior art keywords
formula
compound
carbon atoms
group
general formula
Prior art date
Application number
KR1019820001506A
Other languages
English (en)
Other versions
KR900000274B1 (ko
Inventor
에드워드 제퍼리 제임스
코즈릭 안토닌
챨스 윌름셜스트 에릭
Original Assignee
데렉 노르만 에드먼슨
너 부츠 캄파니 피 엘시
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26279045&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR830010065(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 데렉 노르만 에드먼슨, 너 부츠 캄파니 피 엘시 filed Critical 데렉 노르만 에드먼슨
Publication of KR830010065A publication Critical patent/KR830010065A/ko
Application granted granted Critical
Publication of KR900000274B1 publication Critical patent/KR900000274B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
    • C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
    • C07C29/147—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of carboxylic acids or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/40—Halogenated unsaturated alcohols
    • C07C33/50—Halogenated unsaturated alcohols containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/42—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by hydrolysis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/44—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reduction and hydrolysis of nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/227—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
    • C07C49/237—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/527—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
    • C07C49/567—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/40—Unsaturated compounds containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

내용 없음

Description

치료제의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 일반식(Ⅴ)의 케톤을 환원적 아미드화하여 n=0, R2=H, R4=CHO 인 일반식(Ⅰ)화합물을 제조하거나 일반식(Ⅵ)의 케톤 또는 알데히이드를 환원적 아미드화하여 n=1, R4=CHO, R8=H인 일반식(Ⅰ)화합물을 제조함을 특징으로 하여 일반식(Ⅰ)의 화합물 및 그의 약제학적으로 허용할 수 있는 염을 제조하는 방법.
    상기식에서, n=0 또는 1이며, n=0일때, R1은 1내지 6개의 탄소원자를 함유하는 직쇄 또는 측쇄 알킬그룹, 3내지 7개의 탄소원자를 함유하는 사이클로알킬그룹, 사이클로알킬알킬그룹, (이때 사이클로알킬그룹은 3내지 6개의 탄소원자를 함유하며 알킬그룹은 1내지 3개의 탄소원자를 함유한다). 2내지 6개의 탄소원하를 함유하는 알케닐 또는 알키닐 그룹, 또는 다음 일반식(Ⅱ)의 그룹이며,
    이때, R9와 R10은 같거나 다를 수 있으며 H, 할로 또는 1내지 3개의 탄소원자를 가지는 알콕시그룹이다.
    n=1일때, R1은 H 또는 1내지 3개의 탄소원자를 함유하는 알킬그룹이며, R2는 H 또는 1내지 3개의 탄소원자를 함유하는 알킬그룹이고, R3와 R4는 같거나 다를수 있으며, H, 1내지 4개의 탄소원자를 함유하는 알케닐그룹, 3내지 6개의 탄소원자를 가지는 알키닐그룹, 환이 3내지 7개의 탄소원자를 함유한 직쇄 또는 측쇄 알킬그룹, 3내지 6개의 탄소원자를 함유하는 사이클로알킬그룹, 일반식 R11CO그룹(이때 R11은 H이다)이거나, R3및 R4는 이들이 결합되어 있는 질소원자와 함께 환중에 5 또는 6개의 원자를 가지는 임의 치환된 헤테로사이클환을 형성하는데 이때 환은 질소원자 이외에 다른 헤테로원자를 함유할 수도 있으며; R5와 R6는 같거나 다를수 있으며, H, 할로, 트리플루오로메틸, 1내지 3개의 탄소원자를 가지는 알킬그룹, 1내지 3개의 탄소원자를 함유하는 알콕시 또는 알킬티오그룹, 페닐그룹이거나, R5및 R6는 이들이 결합된 탄소원자와 함께 하나이상의 할로그룹, 1내지 4개의 탄소원자를 함유하는 알킬 또는 알콕시그룹에 의해 임의 치환된 제2의 벤젠환을 형성하거나 제2벤젠환의 치환체는 이들이 결합되어 있는 2개의 탄소원자와 함께 또 다른 벤젠환을 형성할 수 있으며, R7과 R8은 같거나 다를수 있으며, H 또는 1내지 3개의 탄소원자를 함유하는 알킬그룹이다.
  2. 일반식(Ⅴ)의 케톤을 환원적 아민화하여 n=0, R2=H인 일반식(Ⅰ) 화합물을 제조하거나 일반식(Ⅵ)의 케톤 또는 알데하이드를 환원적 아민화하여 n=1, R8=H인 일반식(Ⅰ)화합물을 제조함을 특징으로 하여 일반식(Ⅰ)화합물을 제조하는 방법.
    상기식에서, n,R1,R2,R3,R4,R5,R6,R7및 R8은 제1항에서 정의된 바와 같다.
  3. 일반식(Ⅶ)의 화합물을 환원시킴을 특징으로 하여 일반식(Ⅰ)의 화합물을 제조하는 방법.
    상기식에서, n,R1,R2,R3,R4,R5,R6,R7및 R8은 제1항에서 정의된 바와 같고,
    a) Z 가 일반식 -CR1=NOH그룹 또는)그외 에스테르 또는 에테르인 경우, n=0이고 R2,R3및 R4가 H인 일반식(Ⅰ)의 화합물이 수득되고,
    b) Z 가 일반식 -CR1=NR3의 그룹인 경우, n=0이고 R2및 R4가 H인 일반식(Ⅰ)의 화합물이 수득되고
    c) Z 가 일반식 -CR1=NY의 그룹(Y는 유기금속 시약으로부터 유도된 금속함유 잔기를 나타낸다)인 경우, n=0이고 R2,R3및 R4가 H인 일반식(I)의 화합물이 수득되고
    d) Z 가 일반식 -CR1R2CN의 그룹인 경우, n=1이고 R3,R4,R7및 R8이 H인 일반식(Ⅰ)의 화합물이 수득되고
    e) Z 가 일반식 -CR1R2CR7=NOH 또는 그의 에스테르 또는 에테르인 경우, n=1이고, R2,R4및 R8이 H인 일반식(Ⅰ)의 화합물이 수득되고
    f) Z 가 일반식 -CR1R2CR7=NR3의 그룹인 경우 n=1이고, R4및 R8이 H인 일반식(Ⅰ)의 화합물이 수득되고
    g) Z 가 일반식 -CR1R2CR3CR7=NY(Y는 유기금속 시약으로부터 유도된 금속함유잔기를 나타낸다)의 그룹인 경우, n=1이고 R3,R4및 R8은 H인 일반식(Ⅰ)의 화합물이 수득된다.
    h) Z 가 일반식 -CR1R2CONR3R4의 그룹인 경우, n=1이고 R7및 R8은 H인 일반식(I)의 화합물이 수득된다.
  4. 제3항에 있어서, Y가 MgBr 또는 Li임이 특징인 방법.
  5. 유기금속 시약을 일반식(Ⅶ)의 이민과 반응시킨후 생성물을 가수분해 시킴을 특징으로하여 n이 O인 일반식(Ⅰ)화합물을 제조하는 방법.
    상기식에서, n,R1,R2,R3,R4,R5,R6,R7및 R8은 제1항에서 정의된 바와 같다.
  6. 제5항에 있어서, 유기금속 시약이 일반식 R1MgBr인 그리나드 시약이거나 일반식 R1Li인 유기리튬 화합물임이 특징인 방법.
  7. 유기금속 시약을 일반식(Ⅸ)의 이민과 반응시킨후 생성물을 가수분해시킴을 특징으로하여 n이 1인 일반식(Ⅰ)화합물을 제조하는 방법.
    상기식에서, n,R1,R2,R3,R4,R5,R6,R7및 R8은 제1항에서 정의된 바와 같다.
  8. 제7항에 있어서, 유기 금속 시약이 일반식 R7MgBr인 그리나드 시약이거나 일반식 R7Li인 유기리튬 화합물임이 특징인 방법.
  9. 일반식(Ⅹ)의 아미드를 탈카복실화적으로 전위시켜 n=0인 일반식(Ⅰ)의 아민을 제조하거나, 일반식(XI)의 아미드를 탈카복실화 적으로 전위시켜 n=1인 일반식(Ⅰ)의 아민을 제조하거나, 나트륨 이자이드를 일반식(XⅡ)의 산 클로라이드와 반응시켜 생성된 아실아자이드를 탈카복실화적으로 전위시켜 n=0인 일반식(Ⅰ)의 아민을 제조하거나, 나트륨 이자이드를 일반식(XⅢ)의 산 클로라이드와 반응시켜 생성된 아실 아자이드를 탈카복실화적으로 전위시켜 n=1인 일반식(Ⅰ)의 아민을 제조함을 특징으로하여 일반식(Ⅰ)의 화합물을 제조하는 방법.
    상기식에서, n,R1,R2,R3,R4,R5,R6,R7및 R8은 제1항에서 정의된 바와 같다.
  10. 하이드라조 산을 일반식(XⅣ)의 카복실산과 반응시켜 n=0인 일반식(Ⅰ)의 아민을 제조하거나, 하이드라조산을 일반식(XV)의 카복실산과 반응시켜 n=1인 일반식(Ⅰ)의 아민을 제조함을 특징으로 하여 일반식(Ⅰ)의 화합물을 제조하는 방법.
    상기식에서, n,R1,R2,R3,R4,R5,R6,R7및 R8은 제1항에서 정의된 바와 같다.
  11. R4가 -CHO인 일반식(Ⅰ)화합물을 가수분해 시킴을 특징으로 하여 R4가 수소인 일반식(Ⅰ)화합물을 제조하는 방법.
    상기식에서, n,R1,R2,R3,R4,R5,R6,R7및 R8은 제1항에서 정의된 바와 같다.
  12. R4가 -CHO인 일반식(Ⅰ)화합물을 환원시킴을 특징으로 하여 R4가 메틸인 일반식(Ⅰ)화합물을 제조하는 방법.
    상기식에서, n,R1,R2,R3,R4,R5,R6,R7및 R8은 제1항에서 정의된 바와 같다.
  13. R3및 R4중의 하나 또는 둘다다 수소인 일반식(Ⅰ)화합물을 목적하는 화합물로 전환시킴을 특징으로 하여 R3및 R4중의 하나 또는 둘다다 수소이외의 기인 일반식(Ⅰ)화합물을 제조하는 방법.
    상기식에서, n,R1,R2,R3,R4,R5,R6,R7및 R8은 제1항에서 정의된 바와 같다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR828201506A 1981-04-06 1982-04-06 1-(1-아릴사이클로부틸)알킬아민 유도체의 제조방법 KR900000274B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB81-10709 1981-04-06
GB8110710 1981-04-06
GB8110709 1981-04-06
GB8110710 1981-04-06
GB8110709 1981-04-06

Publications (2)

Publication Number Publication Date
KR830010065A true KR830010065A (ko) 1983-12-26
KR900000274B1 KR900000274B1 (ko) 1990-01-24

Family

ID=26279045

Family Applications (1)

Application Number Title Priority Date Filing Date
KR828201506A KR900000274B1 (ko) 1981-04-06 1982-04-06 1-(1-아릴사이클로부틸)알킬아민 유도체의 제조방법

Country Status (40)

Country Link
KR (1) KR900000274B1 (ko)
AT (1) AT382612B (ko)
AU (1) AU545595B2 (ko)
BG (2) BG40651A3 (ko)
CA (1) CA1248955A (ko)
CH (1) CH652117A5 (ko)
CS (1) CS244672B2 (ko)
CY (1) CY1408A (ko)
DD (1) DD208348A5 (ko)
DE (1) DE3212682A1 (ko)
DK (1) DK161770C (ko)
ES (5) ES511152A0 (ko)
FI (1) FI77223C (ko)
FR (1) FR2504920B1 (ko)
GB (1) GB2098602B (ko)
GE (1) GEP19970661B (ko)
GR (1) GR76697B (ko)
HK (1) HK13888A (ko)
HU (1) HU186582B (ko)
IE (1) IE52768B1 (ko)
IL (1) IL65257A0 (ko)
IN (1) IN155773B (ko)
IT (1) IT1235758B (ko)
JO (1) JO1184B1 (ko)
KE (1) KE3753A (ko)
LU (1) LU84070A1 (ko)
MY (1) MY8800048A (ko)
NL (1) NL192201C (ko)
NO (1) NO156785C (ko)
NZ (1) NZ200178A (ko)
PH (1) PH22762A (ko)
PL (2) PL139120B1 (ko)
PT (1) PT74580B (ko)
RO (2) RO84802B (ko)
SE (1) SE452611B (ko)
SG (1) SG67287G (ko)
SU (2) SU1482522A3 (ko)
UA (2) UA7838A1 (ko)
YU (2) YU44336B (ko)
ZW (1) ZW4982A1 (ko)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE56001B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylmethylamine compounds
IE56000B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylalkylamine compounds
GB8412480D0 (en) * 1984-05-16 1984-06-20 Elliott M Pesticides
DK58285D0 (da) * 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
DK119785D0 (da) * 1985-03-15 1985-03-15 Nordisk Gentofte Insulinpraeparat
US5157021A (en) * 1985-03-15 1992-10-20 Novo Nordisk A/S Insulin derivatives and pharmaceutical preparations containing these derivatives
GB2184122B (en) * 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
EP0647134A4 (en) * 1992-06-23 1997-07-30 Sepracor Inc METHODS AND COMPOSITIONS USED TO TREAT DEPRESSION AND OTHER CONDITIONS WITH OPTICALLY PURE SIBUTRAMINE (-).
GB9309749D0 (en) * 1993-05-12 1993-06-23 Boots Co Plc Therapeutic agents
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9524681D0 (en) 1995-12-02 1996-01-31 Knoll Ag Chemical process
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
AU2007200334B8 (en) * 1998-08-24 2010-10-21 Sepracor, Inc. Methods of using and compositions comprising dopamine reuptake inhibitors
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
GB9915617D0 (en) 1999-07-05 1999-09-01 Knoll Ag Therapeutic agents
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
AU2002210816A1 (en) * 2000-11-02 2002-05-15 Torrent Pharmaceuticals Ltd Process for preparation of beta-phenethylamine derivative
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
KR100536750B1 (ko) * 2002-10-05 2005-12-16 한미약품 주식회사 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
FR2870537A1 (fr) * 2004-05-19 2005-11-25 Servier Lab Nouveau procede de synthese du (1s)-4,5-dimethoxy-1-(methyl aminomethyl-)-benzocyclobutane et de ses sels d'addition, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
KR100606533B1 (ko) 2004-08-27 2006-08-01 한올제약주식회사 시부트라민의 개선된 합성방법
KR100606534B1 (ko) 2004-11-01 2006-08-01 한올제약주식회사 생산성을 향상시킨 시부트라민의 개선된 합성방법
KR100618176B1 (ko) * 2004-12-02 2006-09-01 휴먼팜 주식회사 시부트라민 주석산염, 이의 제조 방법 및 이를 포함하는약학적 조성물
US7432398B2 (en) 2005-01-06 2008-10-07 Cj Corporation Inorganic acid salts of sibutramine
CN101626768B (zh) 2006-09-15 2013-08-21 雷维瓦药品公司 环烷基甲胺的合成、使用方法和组合物
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
CN101555214B (zh) * 2008-04-08 2012-07-11 北京嘉事联博医药科技有限公司 苯基环丁基酰胺衍生物及其光学异构体、制备方法和用途
FR2935381B1 (fr) * 2008-08-29 2010-12-17 Servier Lab Nouveau procede de resolution des enantiomerees du (3,4-dimethoxy-bicyclo°4.2.0!octa-1,3,5-trien-7-yl)nitrile et application a la synthese de l'ivabradine
WO2010082216A2 (en) * 2008-12-08 2010-07-22 Matrix Laboratories Ltd Novel salts of sibutramine and their crystal forms
KR101426180B1 (ko) 2009-11-02 2014-07-31 화이자 인코포레이티드 디옥사-비시클로［3.2.1］옥탄-2,3,4-트리올 유도체
RU2642074C2 (ru) * 2011-12-30 2018-01-24 Ревива Фармасьютикалс, Инк. Композиции, синтез и способы применения производных фенилциклоалкилметиламина
FR2993561B1 (fr) * 2012-07-17 2014-10-31 Servier Lab Procede de synthese enzymatique de la (7s)-1-(3,4-dimethoxy bicyclo[4.2.0]octa-1,3,5-triene 7-yl) n-methyl methanamine, et application a la synthese de l'ivabradine et de ses sels

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1124485B (de) * 1960-02-12 1962-03-01 Hoechst Ag Verfahren zur Herstellung von analeptisch wirksamen Phenylcycloalkylmethylaminen
US3526656A (en) * 1967-05-25 1970-09-01 Parke Davis & Co (1-arylcyclobutyl)carbonyl carbamic acid derivatives

Also Published As

Publication number Publication date
YU44253B (en) 1990-04-30
HU186582B (en) 1985-08-28
ZW4982A1 (en) 1982-11-03
ATA132582A (de) 1986-08-15
ES519032A0 (es) 1984-03-01
FI821197L (fi) 1982-10-07
RO84802B (ro) 1984-10-30
IE52768B1 (en) 1988-02-17
SG67287G (en) 1988-02-19
NO821087L (no) 1982-10-07
SU1461372A3 (ru) 1989-02-23
LU84070A1 (fr) 1983-06-07
YU6385A (en) 1985-08-31
PL139120B1 (en) 1986-12-31
NL8201347A (nl) 1982-11-01
ES8407002A1 (es) 1984-08-16
ES519030A0 (es) 1984-08-01
BG40651A3 (en) 1986-01-15
FR2504920A1 (fr) 1982-11-05
ES8406413A1 (es) 1984-08-01
SU1482522A3 (ru) 1989-05-23
PT74580B (en) 1983-12-23
JO1184B1 (en) 1983-11-30
NL192201B (nl) 1996-11-01
RO89436A2 (ro) 1986-06-30
PL240079A1 (en) 1983-09-12
IT1235758B (it) 1992-09-28
PH22762A (en) 1988-12-12
CH652117A5 (fr) 1985-10-31
GB2098602A (en) 1982-11-24
ES8305678A1 (es) 1983-04-16
SE8202166L (sv) 1982-11-25
AU545595B2 (en) 1985-07-18
NO156785C (no) 1987-11-25
UA7589A1 (uk) 1995-09-29
FR2504920B1 (fr) 1985-06-28
YU44336B (en) 1990-06-30
PT74580A (en) 1982-04-01
AU8221382A (en) 1982-10-14
SE452611B (sv) 1987-12-07
ES519031A0 (es) 1984-08-16
AT382612B (de) 1987-03-25
CS244672B2 (en) 1986-08-14
FI77223C (fi) 1989-02-10
NL192201C (nl) 1997-03-04
UA7838A1 (uk) 1995-12-26
BG40652A3 (en) 1986-01-15
CA1248955A (en) 1989-01-17
DE3212682A1 (de) 1982-10-21
YU75082A (en) 1985-08-31
DK161770C (da) 1992-02-10
IN155773B (ko) 1985-03-09
DK161770B (da) 1991-08-12
IE820481L (en) 1982-10-06
DE3212682C2 (ko) 1992-03-26
ES511152A0 (es) 1983-04-16
PL235832A1 (en) 1983-09-12
KR900000274B1 (ko) 1990-01-24
ES8403097A1 (es) 1984-03-01
DD208348A5 (de) 1984-05-02
KE3753A (en) 1987-10-02
ES8406414A1 (es) 1984-08-01
IL65257A0 (en) 1983-12-30
DK146482A (da) 1982-10-07
MY8800048A (en) 1988-12-31
NZ200178A (en) 1985-07-31
PL136242B1 (en) 1986-02-28
NO156785B (no) 1987-08-17
CY1408A (en) 1988-04-22
HK13888A (en) 1988-02-26
FI821197A0 (fi) 1982-04-05
IT8248157A0 (it) 1982-04-02
CS245782A2 (en) 1985-08-15
GB2098602B (en) 1984-08-22
GR76697B (ko) 1984-08-28
GEP19970661B (en) 1997-01-04
FI77223B (fi) 1988-10-31
ES519029A0 (es) 1984-08-01
RO84802A (ro) 1984-09-29

Similar Documents

Publication Publication Date Title
KR830010065A (ko) 치료제의 제조방법
KR860001104A (ko) 테트라히드로프탈이미드의 제조방법
JPS5490195A (en) Novel benzodiazepine compound
HUP0002953A2 (hu) Eljárás citalopram előállítására és a használt köztitermékek
KR840004425A (ko) N-알킬-노스코핀의 제조방법
HUP9603389A2 (hu) Eljárás 2-acil-amino-alkohol-származékok előállítására és köztitermékeik
FR2382440A1 (fr) Procede d'obtention de phenates metalliques, notamment de phenates de calcium
GB861561A (en) N-substituted piperidines
KR850002480A (ko) 피라졸-환 알킬화된 피라졸로 퀴놀린의 제조방법
ES433109A1 (es) Un metodo para la obtencion de productos intermedios para la sintesis de nuevos derivados de cromone.
KR840006225A (ko) 페닐사이클로부틸메틸아민 유도체의 제조방법
KR870003107A (ko) 키산틴 유도체의 제조방법
KR850004959A (ko) 아릴옥시-n-(아미노알킬)-1-피롤리딘 및 피페리딘 카복스 아미드 및 카보티오 아미드의 제조방법
KR880007490A (ko) 치환된 아미노프로피온아미드, 이의 제조방법, 이를 함유하는 약제, 이의 용도 및 이의 제조시에 생성된 중간체
ATE99318T1 (de) 4-substituierte-anthracyclinone und anthracyclin- glycoside und verfahren zu ihrer herstellung.
HUP9801253A2 (hu) Eljárás 2-helyettesített-benzo[b]tiofén-származékok és köztitermékeik előállítására
KR840006224A (ko) 페닐 사이클로부틸 알킬아민의 제조방법
KR830007568A (ko) N-[아미노(또는 하이드록시)펜에틸]-1,2,3,4-테트라하이드로이소퀴놀린의 제조방법
ES8105970A1 (es) Procedimiento para preparar acidos metil aminoalcanoicos fluorados.
CA2093048A1 (en) Benzo¢b!thiophen-5-yl derivative and process for producing the same
ATE18208T1 (de) N-(4-hydroxyphenyl)essigsaeureamid-estern aus 5benzoyl-1-methylpyrrol-2-essigsaeure.
JPS5519281A (en) Manufacture of amino acid and ester
Ramasseul et al. A useful protecting group in the preparation of amino-nitroxides
KR950032074A (ko) β-니트로엔아민 및 그의 중간체의 제조 방법
HUP0104064A2 (hu) Eljárás és köztitermékek bisz(oxim)-monoéterek előállítására